SRR818270
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.452
- IL6_JAK_STAT3_SIGNALING+0.434
- ANGIOGENESIS+0.425
- INTERFERON_ALPHA_RESPONSE+0.419
- INTERFERON_GAMMA_RESPONSE+0.398
- ALLOGRAFT_REJECTION+0.397
- TNFA_SIGNALING_VIA_NFKB+0.338
- KRAS_SIGNALING_UP+0.308
- COMPLEMENT+0.302
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.299
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.654
- MYC_TARGETS_V2-0.493
- DNA_REPAIR-0.491
- MYC_TARGETS_V1-0.402
- ADIPOGENESIS-0.375
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.373
- FATTY_ACID_METABOLISM-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.336
- UV_RESPONSE_UP-0.301
- WNT_BETA_CATENIN_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR608598 | GTEX | — | 0.956 |
| 2 | SRR602131 | GTEX | — | 0.949 |
| 3 | SRR1474795 | GTEX | — | 0.941 |
| 4 | SRR1335446 | GTEX | — | 0.926 |
| 5 | SRR1369219 | GTEX | — | 0.923 |
| 6 | SRR615020 | GTEX | — | 0.920 |
| 7 | SRR607445 | GTEX | — | 0.916 |
| 8 | SRR821602 | GTEX | — | 0.913 |
| 9 | SRR1330546 | GTEX | — | 0.912 |
| 10 | SRR599510 | GTEX | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.452 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.434 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.425 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.419 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.398 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.397 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.338 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.308 | Inavolisib | — uncovered |
| COMPLEMENT | 0.302 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.299 | Inavolisib | — uncovered |
| COAGULATION | 0.255 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.217 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.181 | Inavolisib | — uncovered |
| APOPTOSIS | 0.128 | Idelalisib | — uncovered |
| HYPOXIA | 0.106 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.083 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.071 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.037 | Inavolisib | — uncovered |
| MYOGENESIS | 0.017 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.006 | Inavolisib | — uncovered |